Shanghai Medicilon Inc. (SHA:688202)

China · Delayed Price · Currency is CNY

87.00

+9.85 (12.77%)

At close: Jul 10, 2026

69.43% (1Y)

Market Cap	11.44B +150.6%
Revenue (ttm)	1.26B +20.6%
Net Income	-137.67M
EPS	-1.05
Shares Out	131.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,916,306
Open	76.50
Previous Close	77.15
Day's Range	76.20 - 91.80
52-Week Range	48.21 - 91.80
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology service... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 2,504

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688202

Full Company Profile

Financial Performance

In 2025, Shanghai Medicilon's revenue was 1.16 billion, an increase of 12.08% compared to the previous year's 1.04 billion. Losses were -167.83 million, -49.27% less than in 2024.

Financial Statements